Bcr-Abl fusion sequences do not induce immune responses in mice when administered in mouse polyomavirus based virus-like particles

International Journal of Oncology

Volumn 35, Issue 6, 2009, Pages 1247-1256

  Hrusková, Veronika ^a   Morávková, Alena ^a   Babiarová, Katarina ^b   Ludvíková, Viera ^b   Fric, Jan ^a   Vonka, Vladimír ^b   Forstová, Jitka ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

Bcr Abl epitope; Chronic myeloid leukemia; Mouse polyomavirus VLPs

Indexed keywords

BCR ABL PROTEIN; CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; EPITOPE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN VP1; PROTEIN VP3; RECOMBINANT PROTEIN; VIRUS ANTIGEN;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CARBOXY TERMINAL SEQUENCE; CHIMERA; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; POLYOMA VIRUS; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS LIKE AGENT; ANIMAL; CYTOTOXICITY; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; IMMUNOELECTRON MICROSCOPY; IMMUNOLOGY; WESTERN BLOTTING;

ANIMALS; ANTIGENS, VIRAL; BLOTTING, WESTERN; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES; FLUORESCENT ANTIBODY TECHNIQUE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MICROSCOPY, IMMUNOELECTRON; POLYOMAVIRUS; RECOMBINANT PROTEINS;

EID: 73949131500     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000441     Document Type: Article

References (38)

1. Pendergast AM, Muller AJ, Havlik MH, Maru Y and Witte ON: BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell 66: 161-171, 1991.
2. Rojas JM, Knight K, Wang L and Clark RE: Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study. Leukemia 21: 2287-2295, 2007.
3. Kislin KL, Marron MT, Li G, Graner MW and Katsanis E: Chaperone-rich cell lysate embedded with BCR-ABL peptide demonstrates enhanced anti-tumor activity against a murine BCR-ABL positive leukemia. FASEB J 21: 2173-2184, 2008.
4. Bertolotti-Ciarlet A, Ciarlet M, Crawford SE, Conner ME and Estes MK: Immunogenicity and protective efficacy if rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramusculary, intranasaly, or orally to mice. Vaccine 21: 3885-3900, 2003.
5. Casal JI: Use of parvovirus-like particles for vaccination and induction of multiple immune responses. Biotechnol Appl Biochem 29: 141-150, 1999.
6. Pan Q, He K and Huang K: Development of recombinant porcine parvovirus-like particles as an antigen carrier formed by the hybrid VP2 protein carrying immunoreactive epitope of porcine circovirus type 2. Vaccine 26: 2119-2126, 2008.
7. Forstová J, Krauzewicz N, Wallace S, Street AJ, Dilworth SM, Beard S and Griffin BE: Cooperation of structural proteins during late events in the life cycle of polyomavirus. J Virol 67: 1405-1413, 1993.
8. Forstová J, Krauzewicz N, Sandig V, Elliott J, Palková Z, Strauss M and Griffin BE: Polyoma virus pseudocapsids as efficient carriers of heterologous DNA into mammalian cells. Hum Gene Ther 6: 297-306, 1995.
9. Soeda E, Krauzewicz N, Cox C, Stokrová J, Forstová J and Griffin BE: Enhancement by polylysine of transient, but not stable, expression of genes carried into cells by polyoma VP1 pseudocapsids. Gene Ther 5: 1410-1419, 1998.
10. Montross L, Watkins S, Moreland RB, Mamon H, Caspar DL and Garcea RL: Nuclear assembly of polyomavirus capsids in insect cells expressing the major capsid protein VP1. J Virol 65: 4991-4998, 1991.
11. Salunke DM, Caspar DL and Garcea RL: Self-assembly of purified polyomavirus capsid protein VP1. Cell 46: 895-904, 1986.
12. Tsai B, Gilbert JM, Stehle T, Lencer W, Benjamin TL and Rapoport TA: Gangliosides are receptors for murine polyoma virus and SV40. EMBO J 22: 4346-4355, 2003.
13. Boura E, Liebl D, Spísek R, Fric J, Marek M, Stokrová J, Holán V and Forstová J: Polyomavirus EGFP-pseudocapsids: analysis of model particles for introduction of proteins and peptides into mammalian cells. FEBS Lett 579: 6549-6558, 2004.
14. Krauzewicz N, Cox C, Soeda E, Clark B, Rayner S and Griffin BE: Sustained ex vivo and in vivo transfer of a reporter gene using polyoma virus pseudocapsids. Gene Ther 7: 1094-1102, 2000.
15. Heidari S, Vlastos A, Ramqvist T, Clark B, Griffin BE, Garcia MI, Perez M, Amati P and Dalianis T: Immunization of T-cell deficient mice against polyomavirus infection using viral pseudocapsids or temperature sensitive mutants. Vaccine 20: 1571-1578, 2002.
16. Caparrós-Wanderley W, Clark B and Griffin BE: Effect of dose and long-term storage on the immunogenicity of murine polyomavirus VP1 virus-like particles. Vaccine 22: 352-361, 2004.
17. Tegerstedt K, Lindencrona JA, Curcio C, Andreasson K, Tullus C, Forni G, Dalianis T, Kiessling R and Ramqvist T: A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors. Cancer Res 65: 5953-5957, 2005.
18. Neugebauer M, Walders B, Brinkman M, Ruehland C, Schumacher T, Bertling WM, Geuther E, Reiser CO, Reichel C, Strich S and Hess J: Development of a vaccine marker technology: display of B cell epitopes on the surface of recombinant polyomavirus-like pentamers and capsoids induces peptide-specific antibodies in piglets after vaccination. Biotechnol J 1: 1435-1446, 2006.
19. Skrastina D, Bulavaite A, Sominskaya I, Kovalevska L, Ose V, Priede D, Pumpens P and Sasnauskas K: High immunogenicity of a hydrophilic component of the hepatitis B virus preS1 sequence exposed on the surface of three virus-like particle carriers. Vaccine 26: 1972-1981, 2008.
20. Fric J, Marek M, Hrusková V, Holán V and Forstová J: Cellular and humoral immune responses to chimeric EGFP-pseudocapsids derived from the mouse polyomavirus after their intranasal administration. Vaccine 26: 3242-3251, 2008.
21. Daley GQ, van Etten RA and Baltimore D: Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247: 824-830, 1990.
22. Invitrogen: Bac/to/Bac Baculovirus Expression System, 2004.
23. O'Reilly DR, Miller LK and Luckow VA: Baculovirus Expression Vectors. A Laboratory Manual, W.H. Freeman and Co., New York, NY, 1992.
24. Hink WF: Established insect cell line from the cabbage looper, trichuplusia ni. Nature 226: 466-467, 1970.
25. Ludvíková V, Hamsíková E, Sobotková E, Lucansky V, Smahel M and Vonka V: Use of polyclonal rabbit antibodies for detection of the bcr-abl fusion zone in cells transfected with experimental bcr-abl DNA vaccines. Int J Oncol 27: 265-274, 2005.
26. Zal T, Volkmann A and Stockinger B: Mechanisms of tolerance induction in major histocompatibility complex class II-restricted T cells specific for a blood-borne self-antigen. J Exp Med 180: 2089-2099, 1994.
27. Mackova J, Kutinova L, Hainz P, Krystofova J, Sroller V, Otahal P, Gabriel P and Nemeckova S: Adjuvant effect of dendritic cells transduced with recombinant vaccinia virus expressing HPV16-E7 is inhibited by co-expression of IL12. Int J Oncol 24: 1581-1588, 2004.
28. Chen W, Peace DJ, Rovira DK, You SG and Cheever MA: T-cell immunity to the joining region of p210BCR-ABL protein. Proc Natl Acad Sci USA 89: 1468-1472, 1992.
29. Pinilla-Ibarz J, Cathcart K, Korontsvit T, Soignet S, Bocchia M, Caggiano J, Lai L, Jimenez J, Kolitz J and Scheinberg DA: Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 95: 1781-1787, 2000.
30. Cathcart K, Pinilla-Ibarz J, Korontsvit T, Schwartz J, Zakhaleva V, Papadopoulos EB and Scheinberg DA: A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 103: 1037-1042, 2004.
31. Maslak PG, Dao T, Gomez M, Chanel S, Packin J, Korontsvit T, Zakhaleva V, Pinilla-Ibarz J, Berman E and Scheinberg DA: A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease. Leukemia 22: 1613-1616, 2008.
32. Yotnda P, Firat H, Garcia-Pons F, Garcia Z, Gourru G, Vernant JP, Lemonnier FA, Leblond V and Langlade-Demoyen PJ: Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. Clin Invest 101: 2290-2296, 1998.
33. Grünebach F, Mirakaj V, Mirakaj V, Müller MR, Brümmendorf T and Brossart P: BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia. Cancer Res 66: 5892-5900, 2006.
34. Abu-Eisha HM, Butt NM, Clark RE and Christmas SE: Evidence that a BCR-ABL fusion peptide does not induce lymphocyte proliferation or cytokine production in vitro. Leuk Res 31: 1675-1681, 2007.
35. Zeng Y, Feng H, Graner MW and Katsanis E: Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity. Blood 101: 4485-4491, 2003.
36. + tumor cells. Blood 105: 2016-2022, 2004.
37. McLauglin J, Chianese E and Witte ON: In vitro transfornation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc Natl Acad Sci USA 84: 6558-6562, 1987.
38. Scheich F, Duyster J, Peschel C and Bernhard H: The immunogenicity of Bcr-Abl expressing dendritic cells is dependent on the Bcr-Abl kinase activity and dominated by Bcr-Abl regulated antigens. Blood 110: 2556-2560, 2007.